Articles by Daniel Marsh
PN Smart Energy Stock More Than Doubles on Record Volume Surge
Shares of PN Smart Energy (PN) more than doubled on Wednesday, closing at $9.34 after a 131.8% surge. Trading volume hit 11.4 million shares, well above the stated Class A total.
NovaGold Jumps 10% on Deal to Acquire Full Donlin Gold Stake
NovaGold shares surged 10.3% to $6.21 after agreeing to acquire Paulson Advisers' 40% interest in Donlin Gold, increasing legacy shareholders' effective stake to 65%.
SSI Payment Shift: August Disbursement Moved to July 31
August SSI payments of $5.4 billion will be issued July 31, resulting in two payments in July and none in August. Investors should watch for volatility in cash-flow data.
Gerdau Shares Gain as Hydropower Deal Strengthens Energy Cost Hedge
Gerdau's ADR climbed 2.7% to $4.77 after the company acquired a 23.03% stake in hydro generator DFESA for R$154 million, advancing its energy hedging strategy.
Rani Therapeutics Soars 29%, Narrows Nasdaq Compliance Gap to 11%
Rani Therapeutics shares jumped 29.4% to $0.89, reducing the gap to Nasdaq's $1 minimum bid to about 11%. CEO Talat Imran's open-market purchase and promising Phase 1a results for RT-114 fueled the rally.
Advanced Biomed Surges 74.6% After Terminating $25M Equity Facility
Shares of Advanced Biomed (ADVB) jumped 74.6% after the company terminated a $25 million equity facility, removing overhang of potential dilution.
Bank of America Stock Nears 52-Week High, Reducing Buyback Efficiency
Bank of America shares rose 0.6% to $61.57, approaching their 52-week high, which reduces the effectiveness of buyback programs as each dollar repurchases fewer shares.
NIO Stock Drops as Chip Unit GeniTech Stake Valued at $763M
NIO shares declined 2.5% after its remaining 62.7% stake in chip subsidiary GeniTech was valued at approximately $763 million, representing 7.8% of the company's market capitalization.
Arrowhead Surges 23% on Positive Plozasiran Phase 3 Data
Arrowhead Pharmaceuticals (ARWR) shares surged 23% after Plozasiran Phase 3 data showed 79-81% median triglyceride reduction and 78% fewer pancreatitis events.
NuScale Power Drops Below Equity Sale Price Amid Dilution Concerns
NuScale Power shares slipped 1.7% to $8.56, trading below its recent equity sale average of $9.69. Dilution concerns and heavy cash burn overshadow nuclear policy gains.